The shift-left approach to via optimization involves a specialized enhancement platform that operates on the design database ...

Learn how to optimize your PCBA testing strategy by combining In-Circuit Testing, Functional Testing with Bed-of-Nails or Flying Probe Testers.

As design engineers push more power, processing capability, and functionality into smaller electronic assemblies, the PCB interconnect becomes a critical reliability and manufacturing decision. It ...

The president banned CNN, MS NOW and Politico from accessing the White House on Sept. 18 CHARLY TRIBALLEAU / AFP via Getty Melania Trump approved a CNN reporter’s credentials for her event at the UN ...

Trump told reporters that U.S. and Iranian officials held a meeting at the U.N. General Assembly as he weighed whether he should “annihilate” the country. NBC News White House correspondent Monica ...

Trump’s outburst follows his decision to ban CNN, MS NOW and Politico reporters from the White House Brendan SMIALOWSKI / AFP via Getty Donald Trump criticized CNN at the UN General Assembly, ...

The Trump administration removed CNN from a planned assignment representing a rotating pool of TV journalists, the latest move by the White House to ban certain news outlets over their coverage of his ...

A simple method involving local anesthesia in the uterus can reduce pain during IUD insertion, according to a new study from Karolinska Institutet, published in the journal JAMA. The method also ...

James L. Line of Howell passed away peacefully at home, August 28, 2026, with his wife Eva, of 61 years, by his side. He was born in Howell on May 1, 1940, to Elgin and Audrey Line. He is survived by ...

Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) ...

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM ...

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer ...